Primary entity: TesofensineAlso known as: NS 2330; Tesomet (combo program)Class: Investigational monoamine reuptake inhibitor — not a peptideCluster: GLP-1 & metabolic
Tesofensine is an investigational oral small-molecule appetite/weight-loss candidate that inhibits reuptake of serotonin, dopamine, and noradrenaline. It is frequently discussed alongside peptide weight-loss drugs in search and forums — but chemically it is not a peptide. It is not FDA-approved in the United States (and has no broad EU marketing authorisation as of November 10, 2026). Partner regulatory activity in Mexico has been publicly discussed as incomplete/ongoing.
If you landed here from “peptides for weight loss,” know that tesofensine is included for cluster literacy, not because it is a peptide hormone analogue.
Not FDA-approved. Not an approved U.S. obesity drug. Historical Phase 2/3 obesity work exists (including a Mexico-partner Phase 3 program reported by Saniona/Medix). Non-U.S. partner-pathway claims have changed over time and are not treated as verified approvals here. A tesofensine-metoprolol combination (Tesomet) has been studied separately; this page does not treat sponsor funding updates as a current trial status.
Key takeaways
- Not a peptide — triple monoamine reuptake inhibitor (small molecule).
- Discussed for obesity / appetite based on clinical programs; also historically explored in neurodegenerative indications.
- Not FDA-approved; do not treat vendor “research” tablets as licensed therapy.
- Cardiovascular themes (heart rate / blood pressure) appear in discussions of tesofensine alone vs Tesomet combination literacy.
- No dosage chart on this site.
Questions this page answers
- What is tesofensine?
- Aliases / Tesomet
- Classification — why it’s on a peptide site
- What it is NOT
- Mechanism
- Evidence ladder
- What has been studied
- Safety literacy
- Regulatory snapshot
- Why no dosages
- Related metabolic agents
- Who for / not for
Who is this profile for — and who is it not for?
For: readers comparing weight-loss pharmacology classes who need accurate “is this a peptide?” literacy.
Not for: anyone seeking a buy link, stimulant-style protocol, or medical advice.
What is tesofensine?
Tesofensine is a triple monoamine reuptake inhibitor (MRI): it increases synaptic availability of serotonin, dopamine, and noradrenaline by blocking their reuptake transporters, without being described as a direct monoamine receptor agonist. That CNS pharmacology is linked in research narratives to appetite, craving, and metabolic regulation.
| Chemistry class | Small-molecule triple monoamine reuptake inhibitor |
|---|---|
| Peptide? | No |
| Route discussed in trials | Oral |
| Historical code | NS 2330 |
| Related combo | Tesomet (tesofensine + metoprolol) |
| U.S. approval | Not approved (as of November 10, 2026) |
Also known as
- NS 2330 — older development code.
- Tesomet — investigational fixed-dose combination of tesofensine + metoprolol (beta blocker), studied for rare hypothalamic / Prader-Willi obesity contexts; program pause reported for funding.
- Mis-tags: “tesofensine peptide” — folk error.
Search engines and AI sometimes file tesofensine under peptides because of weight-loss SERP adjacency. Correct the class first; then discuss evidence.
How is tesofensine classified?
Investigational CNS-acting small molecule. On this site it sits in the glp1-metabolic cluster for educational comparison with peptide anti-obesity drugs — with an explicit not-a-peptide banner.
What is tesofensine not?
| Tesofensine is not… | Why that matters |
|---|---|
| A peptide / GLP-1 agonist | Different chemistry and targets |
| FDA-approved in the U.S. | No U.S. label |
| Synonymous with “safe oral Ozempic” | False analogy |
| Tesomet | Tesomet adds metoprolol |
| Something we dose | Refusal |
How is tesofensine thought to work?
By inhibiting monoamine reuptake, tesofensine is thought to modulate central circuits that regulate appetite and food-seeking, with additional metabolic narratives (e.g., thermogenesis) discussed in sponsor materials. This is not incretin-receptor agonism.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Human Phase 2 | Obesity trials (e.g., TIPO program reports) | Human Mid |
| Human Phase 3 | Partner obesity registration trial reports (Mexico program) | Human — verify publications/reg filings |
| Neurodegeneration history | Earlier Alzheimer/Parkinson exploration | Human Historical / non-obesity |
| Approved U.S. label | None | None |
| Gray-market | Vendor claims | None |
Avoid inventing exact % weight-loss figures in evergreen copy without locked citations.
What has tesofensine been studied for?
Primarily obesity; historically neurodegenerative indications; Tesomet for rare hyperphagic disorders. Studied ≠ approved.
What safety topics come up?
Discussions in clinical development include general tolerability and cardiovascular parameters (heart rate/blood pressure) that motivated combination with metoprolol in Tesomet narratives. CNS-acting appetite drugs require clinician oversight in any legitimate use context. Unregulated products: unknown content. Not medical advice.
What is tesofensine's regulatory status?
- U.S.: Not FDA-approved for obesity (or other indications) as of November 10, 2026; A tesofensine-metoprolol combination has been studied separately; that is not an FDA approval of tesofensine.
- EU: No broad marketing authorisation identified in draft checks.
- Mexico: Partner Medix pathway publicly described with setbacks and resubmission plans.
- Sport: Check WADA; CNS stimulants/related categories may apply depending on substance scheduling — verify current list.
Why doesn't this page include a dosage chart?
No U.S. approved labeled dose for public prescribing; trial doses are not consumer protocols; “tesofensine dosage” queries often seek gray-market instructions. Literacy refusal.
Related lab literacy
Peptide reconstitution pages are not applicable to tesofensine tablets. Linked only for readers comparing clusters: /guides/what-are-peptides/
Related compounds and comparisons
- Semaglutide / Tirzepatide — approved peptide incretin drugs (different class).
- Retatrutide / Eloralintide — investigational peptide candidates.
- Older oral anti-obesity pharmacologies (e.g., historical phentermine-class literacy) — different risk/benefit stories; not equated here.
Frequently asked questions
Is tesofensine a peptide?
No. It is a small-molecule triple monoamine reuptake inhibitor. It appears in weight-loss searches beside peptides, which causes category confusion.
Is tesofensine FDA approved?
No, not in the United States as of November 10, 2026.
How does it work compared with semaglutide?
Semaglutide activates GLP-1 receptors; tesofensine modulates monoamine reuptake in the brain. Different tools, different evidence and risk profiles.
What is Tesomet?
An investigational combination of tesofensine with metoprolol, explored for certain rare obesity disorders; not an approved U.S. therapy, and development status needs verification.
Why is this on a peptide tutorials site?
Because metabolic/weight-loss search demand clusters them together. We publish a literacy profile with an explicit chemistry-class correction.
Why no dosage information?
YMYL policy and lack of U.S. approved labeling for consumer dosing. We will not invent a chart.
Are research-chemical tesofensine products legitimate medicine?
Unregulated products are not FDA-approved medicines. Identity and purity are uncertain.
Who should talk to a clinician instead of reading forums?
Anyone considering weight-loss pharmacotherapy — especially with cardiovascular disease, psychiatric medication use, or pregnancy potential.
Tesofensine is not a peptide and is not FDA-approved in the U.S. Educational only. Disclaimer.
Sources
The sources below were checked against PubMed, DailyMed, or the official agency page on November 10, 2026 (America/Phoenix). Links go to the publisher, PubMed, or the agency record.
- Primary — human Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008. doi:10.1016/S0140-6736(08)61525-1. PMID: 18950853.
- Editorial notice The Lancet. Expression of concern—effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. Lancet. 2013. doi:10.1016/S0140-6736(13)60778-3. PMID: 23561987. Read the 2008 trial together with this notice.
- Anti-doping World Anti-Doping Agency. The World Anti-Doping Code International Standard Prohibited List 2026. Accessed November 10, 2026. Confirm the current list and GlobalDRO before relying on sport status. The 2026 list names tesofensine under S6 stimulants. Tesofensine is not FDA-approved.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Oct 6, 2026 · Regulatory and sport-status wording checked November 10, 2026 against current FDA labels and the 2026 WADA Prohibited List · How we source & update
Educational disclaimer: Educational only. Tesofensine is not a peptide and is not FDA-approved in the U.S. No dosing or buy links. We don’t sell peptides. Read our full disclaimers.